Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Establishment Labs Holdings ( (ESTA) ) has shared an announcement.
On January 14, 2026, Establishment Labs presented at the J.P. Morgan Healthcare Conference, where it shared presentation materials with investors and stakeholders, later furnishing these materials in a Form 8-K filing. The company emphasized that the furnished information, including preliminary financial data and forward-looking elements, is not deemed filed for liability purposes under U.S. securities laws and has not been audited or reviewed by its independent accounting firm, underscoring that investors should not place undue reliance on the preliminary figures.
The most recent analyst rating on (ESTA) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Establishment Labs Holdings stock, see the ESTA Stock Forecast page.
Spark’s Take on ESTA Stock
According to Spark, TipRanks’ AI Analyst, ESTA is a Neutral.
The overall score reflects a mix of strong technical momentum and positive earnings call sentiment, countered by ongoing financial performance challenges and valuation concerns. The company’s strategic initiatives and market expansion efforts are promising, but financial stability remains a key risk.
To see Spark’s full report on ESTA stock, click here.
More about Establishment Labs Holdings
Establishment Labs operates in the healthcare sector, focusing on medical technology and products for the aesthetics and reconstructive markets, including advanced breast implants and related surgical solutions for patients and surgeons worldwide.
Average Trading Volume: 515,776
Technical Sentiment Signal: Buy
Current Market Cap: $1.94B
Find detailed analytics on ESTA stock on TipRanks’ Stock Analysis page.